Company intelligence / Profile preview
Rila Therapeutics
San Francisco, California, United Statesrilatx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
As of May 2024, Rila Therapeutics has dosed the first cohort in a Phase 1 clinical trial of RLA-23174, their first-in-class HIPK2 allosteric inhibitor, in China in collaboration with Yingli Pharmaceutical. The trial is expected to be completed by the end of Q3 2024, with plans to advance to Phase 2 clinical program thereafter[3][5][6].
- Therapeutic areas
- Rare DiseasesNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Yingli PharmaceuticalMount Sinai Innovation PartnersIcahn School of Medicine at Mount Sinai
Beyond the preview
Go deeper on Rila Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rila Therapeutics.